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Risk factors for esophageal cancer include genetic factors (such as tylosis) and infectious agents. A variety of
organisms have been implicated in esophageal carcinogenesis, either directly or indirectly. In this review, we explore
the normal esophageal flora and how it may be controlled, and also the variety of organisms that may affect
esophageal carcinogenesis, either directly or indirectly. The organisms with potential direct effects in squamous cell
carcinoma include human papillomavirus (HPV), Epstein–Barr virus, and polyoma viruses. Interestingly, HPV is
now implicated in esophageal adenocarcinoma (EAC), not in its initiation but in the development of dysplasia, in
which HPV33 in particular has been associated. Indirectly, Helicobacter pylori has been associated with EAC by,
initially, causing increased acid secretion that increases acid reflux, and by reducing lower esophageal sphincter
pressure, which increases gastroesophageal reflux; the latter increases the risk of Barrett’s esophagus, and hence EAC.
Conversely, subsequent atrophic gastritis may normalize that risk.
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Introduction
In looking at the role of infection in esophageal
carcinogenesis, it is important to first establish the
nature of the normal flora dwelling in all parts
of the esophagus and determine if, or how, they
change. It is then necessary to look at infectious
organisms that may or may not be normally found
and determine if they have a role in esophageal car-
cinogenesis and what the strength of any potential
association is. In addition, flora and potential
pathogens from adjacent organs may also affect
the risk of esophageal carcinoma, since oral organ-
isms such as human papillomavirus (HPV), and
potentially other viruses such as Epstein–Barr virus
(EBV), can reach the esophagus, either directly in
saliva or indirectly systemically, to play a role in
esophageal carcinogenesis. Conversely, gastric Heli-
cobacter infection can affect both gastric acid pro-
duction and the lower esophageal sphincter; so it
may contribute to both gastric acid levels as well
as gastric contents that may be refluxed into the
esophagus, which includes activated pancreatico-
biliary secretions and enteric organisms reaching
doi: 10.1111/nyas.13858
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the stomach by duodenogastric reflux. We will end
by exploring genetic factors such as tylosis and
the role of Barrett’s esophagus (BE) in esophageal
carcinoma.
The normal esophageal microbiota (EM)
and its role in esophageal diseases
The human microbiota
It is now well recognized that the human microbiota
(HM), defined as the complex and dynamic ecosys-
tem that includes trillions of bacteria, archaea,
fungi, and viruses with which the human body
interacts with in symbiotic and mutualistic relation-
ships, plays a central role in shaping host physiology
and health.1 Due to its products and its interaction
with the host, the HM has been also referred to as
an additional organ, even a “second genome”, since
the HM genetic content (collectively termed micro-
biome) is more than 100-fold larger than the human
genome.2 Research in this area has been greatly cat-
alyzed by the recent technological advancements of
multiomic sciences, particularly of high-throughput
culture-independent metagenomic approaches,
which have greatly contributed to expanding our
knowledge of the content, diversity, and functions of
the HM.3
In the last decade, large-scale projects such as the
MetaHIT 4 and the Human Microbiome Project2
have provided an exhaustive description of the com-
plex interplay between the HM and host. For exam-
ple, the gut microbiota (the human body’s dens-
est microbial habitat) has an impact on human
physiology by participating in the biosynthesis of
vitamins and essential amino acids,5 by train-
ing and modulating the immune system,6 and by
protecting against epithelial injuries and invading
pathogens.7
Advancements from these projects have also con-
tributed to identify some of the general features of
the HM. First, the HM shows substantial qualitative
and quantitative variations through the body axes
and among individuals, with thousands of different
species having a specific spatial distribution8,9
and being unculturable in most cases. Second,
important age-dependent compositional variations
have been observed over the human life span, with a
stable, high level of microbial richness in adulthood,
and a lower level in infants and elderly individuals.10
Third, the HM is a highly dynamic ecosystem,
being able to restore its original healthy equilibrium
(a phenomenon known as resilience) following a
perturbation of its normal structure (dysbiosis).
A common feature of dysbiotic states is a marked
decrease of overall microbial diversity, which can
be triggered by a plethora of different factors such
as infections, antibiotic treatment, and other envi-
ronmental factors.11,12 These microbial imbalances
were found to be associated with a number of
human pathological conditions. Dysbiotic states
have been linked to obesity, inflammatory bowel
diseases, Crohn’s disease (CD), type II diabetes,
liver diseases, bacterial infections, and many other
pathological states.7,13–16 However, apart from the
fundamental role of gut microbiota in preventing
colonization and infection by spore-forming
toxigenic strains of Clostridium difficile,17 causative
relationships between dysbiosis and disease remain
to be established.
The EM and its potential role in major
esophageal diseases
Historically, the esophagus was thought to be a rela-
tively sterile organ due to its anatomical and physio-
logical characteristics. The first studies investigating
the microbiological content of the esophagus were
performed using culture-dependent methods in the
1980s.18,19 The few observed organisms, mainly of
genus Streptococccus, were supposed to be derived
from the oral cavity following the transient passage
of saliva and food. It was only in 2004 that Pei and
Osias, through microscopic examinations of stained
biopsies, clearly showed that the presence of bacte-
ria had an intimate association with the esophageal
mucosa.20 These findings provided strong evidence
for a resident microbiota colonizing the esopha-
gus, as observed in other gastrointestinal tracts, and
paved the way for subsequent studies aimed at defin-
ing the composition and structure of the microbiota
in the normal esophagus and its potential role in the
onset or outcome of many esophageal diseases.
Information about healthy EM remains limited,
with very few studies enrolling healthy asymp-
tomatic subjects and using culture-independent
techniques. Previous findings21 were confirmed by
recent studies based on next-generation sequencing
(NGS),22 which demonstrated that the healthy
esophagus is dominated by the genus Streptococcus
(phylum Firmicutes), in association with Prevotella
(phylum Bacteroidetes) and Veillonella (phylum
Firmicutes), although at less abundance. Other
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Table 1. Most frequently detected microorganisms at the













aAccording to the results of NGS-based studies41,50 investigating
normal esophageal microbiota.
frequently identified genera included Fusobacterium
(phylum Fusobacteria), Haemophilus, Neisseria
(phylum Proteobacteria), and Porphyromonas (phy-
lum Bacteroidetes) (Table 1), reinforcing the notion
that the esophageal microenvironment is phylo-
genetically closely related to that found in the
oropharynx.23
The potential role of EM in participating in dis-
ease initiation or promotion has been more thor-
oughly investigated in relation to gastroesophageal
reflux, since it is the strongest modifiable factor
involved in the pathogenesis of almost all esophageal
diseases.24 Prolonged exposure to gastric acid and
refluxate is known to severely affect the esophageal
mucosa and could elicit marked alterations in
microbial communities residing in the lower esoph-
agus. Although studies on the esophageal microen-
vironment are largely restricted by the need for
invasive procedures for sampling, some microbial
signatures have been identified as potential contrib-
utors to the pathogenesis of gastroesophageal reflux
disease (GERD), BE, and esophageal adenocarci-
noma (EAC).
A pioneering large-scale culture-independent
study, performed by Yang et al. in 2009,25 identified
two distinct patterns of EM: type I, associated with
normal esophagus and characterized by a predom-
inance of Gram-positive taxa, with a high abun-
dance of the genus Streptococcus (79%); and type
II, associated with erosive esophagitis and BE, and
characterized by a predominance of Gram-negative
taxa (mostly from Bacteroidetes, Fusobacteria, and
Proteobacteria phyla), with a marked reduction in
the Streptococcus abundance (30%). Similar findings
were reported in a subsequent study by Liu et al.,26
whereas recognition of the type I and II patterns
was not confirmed by most recent studies employ-
ing NGS methodologies,22,27 possibly due to differ-
ences in patient characteristics (i.e., symptomatic
controls, treatment with proton pump inhibitors).
Most recently, Gall et al. analyzed the compo-
sition of the EM in a cohort of patients with BE
and identified positive and negative correlations for
the Streptococcus–Prevotella ratio with waist-to-hip
ratios and hiatal hernia length, respectively, two
known risk factors for BE and EAC.28 The incidence
of EAC has been rapidly increasing over the past
two decades in Western countries,29 but only a few
culture-independent studies have investigated the
potential role of EM in the progression to esophageal
malignancies.22,30 Blackett et al. reported a signifi-
cant enrichment of Campylobacter concisus in the
early stages of the EAC cascade only (i.e., in GERD
and BE patients); they proposed a specific role for
this pathogen in the BE/EAC cascade. The proposed
pathogenic mechanism consisted in an increase of
the host inflammatory response triggered by the
chronic colonization by C. concisus. The authors
hypothesized that this condition could eventually
induce metaplastic changes in a dysbiotic and pre-
viously injured esophageal mucosa (i.e., columnar
metaplasia characteristic of BE), ultimately favoring
malignant transformation.30 The most recent study
on this topic22 did not confirm an enrichment of any
Campylobacter species in EAC patients, but instead
showed decreased bacterial richness and diversity
compared to controls and BE patients, along with a
significant increase of Lactobacillus fermentum and
lactic acid bacteria in almost half (47%) of EAC
patients. Moreover, the authors did not identify any
differences between the microbiota of BE and EAC
patients and suggested that bacterial taxa with very
low relative abundances, being more difficult to
detect, may potentially contribute to alteration of
the EM in these patients.22
Overall, current data on EM in health and
disease remain limited and a significant gap in
knowledge persists about the primary role of EM in
disease onset and outcome. Although several
hypotheses have suggested how a dysbiotic EM
could promote chronic low-grade inflammation
and/or favor a chronic reflux state by relaxing
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the lower esophageal sphincter in GERD-related
diseases, causation is uncertain. Of note, in addition
to GERD-related diseases, compositional variations
of the EM have been implicated in less common
esophageal diseases and malignancies.31
Several issues remain. Little information is avail-
able about the stability of EM over time and about
any homogeneity of the EM throughout the esoph-
agus. Rare studies have investigated the latter and
evaluated upper and lower esophageal biopsy sam-
ples in healthy subjects,21 normal squamous and
metaplastic mucosa in BE patients,28 or normal
squamous and malignant mucosa in EAC patients.22
In all reported cases, the authors did not identify
significant differences between various esophageal
segments or histotypes.
Long-term longitudinal studies in a large cohort
of patients are therefore needed to answer some
of the open questions. Future studies into the
EM will be prompted by (1) the formulation of
guidelines to cope with the heterogeneous patient
enrollment criteria and sampling procedures; (2)
the implementation of multiomic approaches; and
(3) the development of minimally invasive sam-
pling devices,22 which have proven to be as effec-
tive as esophageal biopsies in capturing the global
diversity observed among esophageal microbial
communities.
The role of Helicobacter in EAC
Since the increase in EAC incidence in Western
countries has paralleled the decrease in Helicobacter
pylori infection, some investigators suggested Heli-
cobacter protects against EAC.32–34 This inverse rela-
tionship is frequently attributed to increased gas-
tric acid production following the eradication of H.
pylori infection. The protective effect is attributed
to decreased gastric acid production secondary to
H. pylori–associated infection, particularly atrophic
pangastritis.32,35,36 This protection is primarily seen
with cag A–positive strains.37,38 Conversely, others
have argued that H. pylori might be the cause of
GERD,39 since the infection adversely affects the
lower esophageal sphincter.40
In practice, the seemingly protective effect of
H. pylori on GERD has not been seen in countries
such as Greece and Turkey, where H. pylori is highly
prevalent.41 In Turkey, H. pylori has no effect on
the prevalence of GERD, although it was better con-
trolled by its eradication.41 H. pylori seems consis-
tently protective against GERD in studies conducted
in the United States and a few studies from Japan,
but inconsistently in studies conducted outside of
the United States or Japan.42
Chronic H. pylori infection causes either hypo-
or hyperchlorhydria, depending upon anatomic site
of infection (gastritis pattern). Antral-predominant
gastritis is associated with hypergastrinemia and
hyperchlorhydria and the pattern typically associ-
ated with the highest risk of GERD.39,43,44 Pangas-
tritis with corpus atrophy, a pattern characteristic
of protection, is also highly associated with gastric
cancer.44,45
Finally, if H. pylori is protective against GERD, its
eradication would cause reflux; yet studies exam-
ining this hypothesis have shown no effect46 or
GERD symptom improvement following eradica-
tion therapy.47 Of note, H. pylori eradication is
usually followed by a significant increase in body
weight.48
Though the time trends seem consistent with the
hypothesis that declining H. pylori prevalence has
led to a rise in BE and increased prevalence of EAC,
these trends could be coincidental and not causally
related. The increased prevalence of BE and EAC
could also be related to the higher prevalence of
obesity and a decrease in lower esophageal sphincter
pressure leading to GERD.49,50 It is also possible that
both processes may be at work.
The role of HPV infection and HPV
vaccines in esophageal squamous cell
carcinoma
Esophageal squamous cell carcinoma (ESCC)
accounts for a majority of esophageal cancer occur-
ring most commonly in the upper two-thirds of
the esophagus. Rare variants of ESCC include: basa-
loid squamous cell carcinoma (BSCC), spindle cell
(squamous) carcinoma (carcinosarcoma), undiffer-
entiated carcinoma, verrucous (squamous) carci-
noma, and carcinoma cuniculatum.51–54
Incidence of ESCC shows wide geographical vari-
ations, ranging from 2.5/100,000 to 250/100,000
in low- (e.g., the United States, Australia) and
high-incidence (e.g., Iran, China, Brazil) countries,
respectively.55,56 The etiological role of HPV in
the carcinogenesis leading to ESCC is still unclear.
To date, great differences in HPV DNA detec-
tion rates in cancerous tissue have been reported,
with a prevalence ranging from 1% to 65% within
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the same region and from 0% to 70% between
different regions.56–59 Two different meta-analyses
showed significant association between HPV infec-
tion and ESCC, with odds ratios of 3.32 and 3.11.57,60
Furthermore, case-control studies showed highly
divergent detection rates of HPV DNA in normal
esophagus (range: 0–58.9%).57
Over the years, different HPV detection meth-
ods with variable specificity and sensitivity have
been applied.61 Today, in situ hybridization (ISH)
and polymerase chain reaction (PCR) are most fre-
quently used, with more reliable results. Neverthe-
less, one should keep in mind that more than 100
HPV strains have been discovered so far. The onco-
genic types are divided into high- and low-risk sub-
types based on cervical, oropharyngeal, and anal
squamous cell carcinoma. In studies focused on
ESCC, only certain strains of HPV (usually type 11,
16, and 18) have been tested, leaving the possibility
of undetected infection by a different HPV type not
included in the test. According to published find-
ings, types 16 and 18 are most frequently observed,
followed by types 11, 31, 33, and 52.57–60
In cervical cancer, p16 overexpression is fre-
quently used as evidence of HPV oncoprotein activ-
ity. In ESCC, however, studies have not been able
to confirm p16 as a reliable marker of transcrip-
tionally active HPV.58,62,63 Furthermore, rates of
double-positive ESCC (namely HPV-positive and
p16-overexpressing) were most commonly found in
only about 5% of carcinomas.58,59 Of note, an incon-
sistent definition of cutoff values for the determina-
tion of p16 overexpression was observed among the
studies.
Concerning rare subtypes of ESCC, only a small
number of studies looking at HPV status have been
published in English. Using ISH or PCR, no HPV
DNA was detected in nine cases of BSCC, 11 cases
of carcinoma cuniculatum, or one case of spindle
cell (squamous) carcinoma, suggesting that HPV
likely does not play a role in the oncogenesis of
these rare variants.53,54,64,65 One report suggested an
association with HPV type 51 for the development
of verrucous carcinoma. The finding of HPV DNA
by PCR, however, was not confirmed in a resection
specimen from the same patient.66
Potential role of vaccines
Bivalent (HPV-16/18; Cervarix R©) and quadriva-
lent (HPV-6/11/16/18; Gardasil R©) vaccines target-
ing the most common HPV types have been found
to be effective in cervical, vulvar, oral, and anal
cancer.67 Studies investigating the efficacy of these
two vaccines also observed cross-protection against
some nonvaccine but oncogenic HPV types (e.g.,
HPV-31/33/45). More recently, nonavalent (HPV-
6/11/16/18/31/33/45/52/58; Gardasil R©) vaccine has
been approved in some countries. Unfortunately,
studies evaluating the efficacy of HPV vaccines in
the oncogenesis of ESCC are lacking. Prophylactic
vaccination could be promising and beneficial in
the reduction of HPV-associated ESCC in regions
with high ESCC incidence, and this effect could be
increased in countries where both males and females
are vaccinated.
HPV and adenocarcinoma of the
esophagus
GERD and BE have traditionally been considered
the most important risk factors for EAC, the fastest
growing cancer in the Western world and occur-
ring against a backdrop of progressive reduction in
the risk of malignancy associated with BE but no
reduction in mortality from EAC, using the pre-
vailing screening and surveillance guidelines.68 The
recently published link between high risk HPV and
Barrett’s dysplasia (BD)/cancer may be one of the
missing strong risk factors responsible for the sig-
nificant rise of EAC since the 1970s, as has been
the case with head and neck squamous cell carcino-
mas, a significant minority of which are also virally
associated.69,70
Previously published studies using PCR tech-
niques that showed negative results were due to poor
tissue classification, suboptimal testing method-
ology exacerbated by low viral load, old specimen
samples susceptible to DNA/RNA degradation, as
well as ethnic and regional variations.71–75 Instead
of fresh frozen material, almost all of these ret-
rospective investigations used paraffin-embedded
tissue, which yields a significant false negative HPV
PCR DNA result.68 Some studies misclassified as
negative used only nondysplastic BE. Barrett’s
metaplastic tissue has never been shown to be
HPV-associated.71,72 Others have detected only low-
risk HPV types without seeking evidence of viral
integration or replication.76 Interestingly, a system-
atic review reported HPV prevalence rates of 35% in
174 cases of EAC, not dissimilar to other findings.77
Another systematic review that included 19 studies
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Figure 1. In situ hybridization detection of transcriptional
activity of hr-HPV (i.e., E6/E7 mRNA) in esophageal adeno-
carcinoma. Positive staining is diffusely present (with a punc-
tate/granular appearance) in the nuclei and cytoplasm (image
courtesy of Professor S. Rajendra).
concluded that the pooled prevalence of HPV in
EAC was 13%. The authors suggested that the low
prevalence rate may have been caused by small sam-
ple sizes and compromised detection methods.78
An important reason for why it is difficult to detect
HPV DNA via PCR is the low viral load in glandular
tissue,79 which is very much less than in the uterine
cervix, anal canal, and oropharynx, which all consist
of squamous epithelium. It is well known that HPV
has a predilection for squamous epithelium, though
ISH analysis of HPV DNA and E6/E7 mRNA has
clearly demonstrated viral tropism for esophageal
glandular tissue (Figs. 1 and 2).
In 2013, one study demonstrated that biologically
active, high-risk HPV (hr-HPV) is strongly asso-
ciated with BD and EAC.70,79 Viral–host genome
integration was found to be an early event.79 An
increasing HPV viral load and integration gradient
was significantly linked with disease severity as per
the Barrett’s metaplasia–dysplasia–adenocarcinoma
pathway.79 Moreover, persistent hr-HPV infection
and p53 overexpression predicted treatment failure
after endoscopic ablation of BD and EAC.80 The
vast majority of BD and EAC specimens contain-
ing biologically active hr-HPV were shown to have
wild-type TP53, which is typical of HPV-driven
cancers.60,68,81 Recently, it was demonstrated that
HPV-associated EAC harbors a distinct profile of
molecular aberrations/genomic abnormalities com-
pared with HPV-negative EAC, indicating differ-
Figure 2. DNA in situ hybridization image revealing the pres-
ence of high-risk human papillomavirus genome in a Barrett’s
dysplasia/esophageal adenocarcinoma specimen. Absence of
staining in adjacent squamous epithelium suggests viral tropism
for esophageal glandular tissue (image courtesy of Professor S.
Rajendra).
ent biological mechanisms of tumor formation.82
HPV-positive EAC was shown to have half the
number of nonsilent somatic mutations than HPV-
negative esophageal cancers. TP53 aberrations were
absent in the HPV-positive EAC group, whereas
50% of the HPV-negative EAC patients exhibited
TP53 mutations. Viral integration analysis identi-
fied hybrid sequences containing HPV16 and the
human genome, providing evidence for a host–
viral interaction.82 Active hr-HPV involvement in
BD/EAC is identified by a characteristic molecu-
lar signature consisting of retinoblastoma protein
(degraded by the E7 oncoprotein) pathway alter-
ations, for example, upregulation of p16INK4A as well
as downregulation of pRb wild-type and p53 (the
target of the E6 viral cancer protein; Fig. 1).83 Thus,
hr-HPV is considered a risk factor for BD and EAC
(in 20–25% of patients), along with chronic reflux,
obesity, and smoking.84
The role of EBV in esophageal cancer
Biological background of EBV infection in
gastrointestinal carcinomas and the role of
EBV in esophageal carcinomas
EBV is one of the nine known viruses in the fam-
ily of human Herpesviridae (HHV-4). These DNA
viruses typically show latent, recurrent infections—
hence the term herpes, derived from the Greek
word herpein (= to creep). EBV affects over 95%
of the adult population. While childhood infection
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with EBV is usually symptomless or indistinguish-
able from other mild, brief childhood illnesses, its
manifestation during adolescence as infectious
mononucleosis may present more severe and partly
long-lasting symptoms.85,86 EBV is also associated
with specific forms of cancer, including both hema-
tologic and epithelial malignancies, and it is esti-
mated that worldwide over 200,000 cancer cases and
up to 2% of cancer-related deaths per year may be
attributed to infection with the virus.87,88
EBV infection occurs by oral transfer of saliva,
and genital secretions. EBV is a lymphotropic virus
that infects B lymphocytes via CD21/CR comple-
ment receptor type 2. After an initial lytic infection,
EBV latency persists in B cells for the rest of the host’s
life. This direct infection of B cells can later cause
suppression of somatic hypermutation after latency,
leading to a continuous proliferation of the infected
clone eventually resulting in the establishment of
a lymphoma. Another possibility for lymphoma-
genesis is the direct infection of memory B cells,
with subsequent induction of proliferation. Lym-
phomas that are typically associated with EBV are
Burkitt lymphoma, classical Hodgkin lymphoma,
EBV-positive posttransplantation lymphoma, and
some cases of diffuse large B cell lymphomas and T
cell lymphomas.88
The majority of EBV-associated cancers, how-
ever, are epithelial malignancies, and the most fre-
quent types by far are nasopharyngeal carcinomas
and gastric adenocarcinomas.87 Epithelial cells lack
CD21 as a surface receptor for EBV infection, but
the virus may enter epithelial cells using saliva IgA as
a vehicle, by the interaction with integrins on polar-
ized epithelial cells or using other virus components
as ligands of specific epithelial surface receptors.89
There is also evidence of a shuttle between infected
B cells releasing EBV and epithelial cells being
infected, and vice versa. This cell-to-cell, contact-
mediated EBV infection is also far more effective
compared to the cell-free infection mode of B cell
infection.90 This also explains the fact that EBV
infection of epithelial cells predominantly occurs in
anatomic sites with well-established surrounding
lymphatic tissue (e.g., the nasopharyngeal tract or
mucosa-associated lymphatic tissue) or in associa-
tion with chronic infections (e.g., chronic gastritis).
On a molecular level, EBV infection causes a large
variety of events.91 This includes mutations (e.g.,
PIK3CA, ARID1A, AKT2, and many others), methy-
lation of both the EBV and the host genome, ampli-
fications (e.g., JAK2, CD274, PDCD1LG2, and oth-
ers), deletions (e.g., PTEN, MACROD2, and others),
and deregulation of the expression of a large vari-
ety of mRNAs and microRNAs (miRNAs).91–93 This
hypermutated status of EBV-associated carcinomas
is the underlying reason for the well-established
inflammatory infiltrate that often accompanies
these types of cancers, resulting in the typical lym-
phoepithelial phenotype.
The association of EBV with a subset of gastric
adenocarcinomas and adenocarcinomas of the gas-
troesophageal junction has been well documented
over the last few decades, and EBV positivity now
also defines a specific molecular subtype of gas-
tric adenocarcinoma that is highly distinct from
EBV-negative tumors.94,95 The association of EBV
with esophageal carcinoma, however, is less clearly
defined, as the relatively few studies on this mat-
ter show conflicting results.78,96,97 These discrep-
ancies can be primarily attributed to the different
methods used to detect EBV. Older studies rely-
ing on PCR-based methods lack specificity, as EBV-
positive lymphocytes are found in the majority of
the adult population. Thus, the detection of EBV-
positive tumor infiltrating lymphocytes in tumor
tissue by PCR results in false positive results for
EBV presence in the neoplastic cells. In contrast,
direct evidence of EBV in individual tumor cells
by ISH or immunohistochemistry is more specific,
with the disadvantage of being less sensitive. Studies
focusing on the detection of EBV within tumor cells
suggest that EBV is not associated with EAC and
conventional ESCC.78,98 However, the very rare
squamous cell carcinoma variant of lymphoep-
ithelial carcinoma or lymphoepithelioma-like car-
cinoma has been shown to be associated with
EBV infection in several studies.97,99–101 This fre-
quently EBV-positive tumor is defined as an undif-
ferentiated or poorly differentiated squamous cell
carcinoma with a prominent lymphoplasmacytic
infiltrate, morphologically similar to nasopha-
ryngeal lymphoepithelial carcinoma. It is more
prevalent in Asia, has a distinct submucosal-like
appearance on endoscopy, and is associated with an
improved outcome in comparison to conventional
squamous cell carcinoma.99 Whether EBV-positive
esophageal lymphoepithelial carcinoma features
high levels of PD-L1/PD-L2 expression analogously
to EBV-positive gastric adenocarcinoma and thus
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Polyomavirus (PyV) is a nonenveloped double-
stranded DNA virus that infects birds, mammals,
and fish. There are 73 recognized species, of which
13 infect human hosts and are grouped together as
the human polyomaviruses (HPyVs).102 HPyVs are
highly prevalent in aqueous environments, includ-
ing urban sewage, and have been isolated from
different surface water samples.103 They can persist
as latent infection for a long time without causing
disease in hosts. The genome of most PyVs consists
of approximately 5000 base-pairs and encodes reg-
ulatory (large and small T antigen) and structural
capsid proteins (VP1, VP2). Some HPyVs also have
an additional regulatory protein, agnoprotein.104
BK virus (BKV) and the JC virus (JCV) were the
first two HPyVs isolated from human hosts. The
oncogenic potential of these two HPyVs, along with
a third common type of HPyV, Merkel cell PyV
(MCPyV), is well documented in cell culture and
animal model studies. MCPyV has a strong associ-
ation with cancer in its natural host; approximately
80% of Merkel cell carcinoma tumors are positive
for MCPyV.105 McPyV has also been isolated
from tissue samples of normal upper aerodigestive
tract, including oral cavity and esophagus.106 The
etiology of esophageal cancer is multifactorial,
and the role of viruses is still controversial. With
regard to the role of HPyVs, two different studies
have demonstrated a causal association between
McPyV and JCPyV in esophageal carcinogenesis.
In a cross-sectional study, Yahyapour et al. analyzed
96 formalin-fixed resection specimens from ESCC
and benign conditions. HPV and McPyV DNA
load in tissue samples were measured by using
the real-time PCR technique. MCPyV DNA was
detected in 45.1% of esophageal cancer samples and
35.6% of benign pathology samples. There was no
statistically significant difference between the mean
MCPyV DNA load (P = 0.353) of both sample
types. Esophageal samples with normal histology
were negative for MCPyV DNA. HPV DNA was
detected in 31.4% of cancer samples and 44.4%
in the benign samples. Concomitant infection
with HPV and MCPyV was seen in 15.8% of
cancer and 17.8% of benign esophageal samples.107
This study provides some evidence for MCPyV
infection in esophageal tissues, either alone or
with HPV, however, an unequivocal contribution
to esophageal carcinogenesis is debatable; more
extensive studies are needed.
JCV in esophageal carcinoma
A subtype of HPyV, JCV is a well-recognized
causative agent of progressive multifocal leukoen-
cephalopathy in immunocompromised hosts.108
Subclinical infection in humans is known to be
present in 85–90% of the population worldwide.
In addition to early and late coding genes, the JCV
genome also contains the small regulatory protein
agnoprotein. Its oncogenic potential has been stud-
ied in experimental animals and is associated with
human brain tumors. JCV has also been found
in normal mucosa of the gastrointestinal tract.8
T-antigen protein of JCV has been isolated from
colon carcinomas.109,110
In a study performed using immunohistochem-
ical and PCR techniques, Del Valle et al. demon-
strated the presence of JCV DNA sequences and pro-
teins in normal, benign, and cancer pathology tissue
samples. Esophageal tissue biopsy samples from
70 subjects, including normal esophagus, a varied
range of benign conditions, adenocarcinoma, and
squamous cell carcinoma were studied. JCV DNA
sequences were found in cells from normal esopha-
gus, benign esophageal diseases, and esophageal car-
cinoma. Notably, expression of active viral proteins,
including T antigen and agnoprotein, was detected
in many of the cancer samples.111 The oncogenic
potential of these proteins might have contributed
to the carcinogenesis in this study.112 Conclusive
proof of their specific role in esophageal carcino-
genesis is lacking and further studies are warranted.
Esophageal carcinoma in tylosis
Tylosis (hyperkeratosis palmaris et plantaris) is
a rare inherited condition characterized by focal
nonepidermolytic thickening of the skin in the
palms and soles.113,114 Tylosis with esophageal can-
cer (TOC) was first described in two British families
(Liverpool, the United Kingdom).115,116 Tylosis is
associated with a very high lifetime risk of devel-
oping squamous cell carcinoma of the esophagus:
95% at the age of 65 in one Liverpool family.115 Its
clinical aspects, diagnosis, and management have
been reviewed by Ellis et al. 117
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Figure 3. Keratinocyte/squamous cell with a mutated
RHBDF2 gene (in the nucleus) that encodes an inactive rhom-
boid protein, leading to (1) increased shedding of ADAM17
substrates, including EGF-family growth factors, and increased
EGFR activity; and (2) shedding of TNF receptors from cell
surfaces, muting the cellular response to TNF- .
It is inherited as an autosomal dominant trait
with complete penetrance. Missense mutations have
been described in rhomboid family member 2
(RHBDF2) located on 17q25.1, which encodes an
inactive rhomboid protein 2 (iRhom2).118 RHBDF2
is involved in the regulation of the secretion of sev-
eral ligands for the epidermal growth factor recep-
tor. Mutations in RHBDF2 inhibit tumor necro-
sis factor alpha (TNF-; i.e., dampens its cell
response) and enhance epidermal growth factor
receptor (EGFR) activity.119
TOC-associated iRHOM2 mutations increase the
maturation and activity of ADAM metallopep-
tidase domain 17 (ADAM17), a protease that
catalyzes the shedding of various transmembrane
proteins from the surface of cells, which leads to
a significant increase in the shedding of ADAM17
substrates from epidermal keratinocytes, including
EGF-family growth factors, and increased EGFR
activity. These features are consistent with the pres-
ence of a constitutive wound-healing-like pheno-
type in TOC epidermis (Fig. 3).119
ADAM17 also catalyzes the shedding of TNF-
and its receptors. Liberation of TNF receptors from
cell surfaces can dampen the cellular response to
TNF-, a cytokine that promotes programmed cell
death (Fig. 1).
Deletions in the cytoplasmic domain of iRhom1
and iRhom2 promote shedding of the TNF recep-
tor by ADAM17.120 Mutated iRhom2 increases
ADAM17 activity, TNF receptor shedding, and
resistance to TNF-induced cell death in fibrosar-
coma cells. Keratinocytes from TOC patients exhibit
increased TNF receptor shedding compared with
cells from healthy donors. It appears that aber-
rant EGFR signaling underlies the predisposition
for ESCC.
Role of BE in ESCC
Squamous carcinoma has been described in patients
with BE in a variety of settings. There are multiple
case reports in the literature describing synchronous
squamous cell carcinoma and adenocarcinoma in
the esophagus with Barrett’s mucosa.121–123 In these
reports, the squamous cell carcinoma did not arise
within the Barrett’s segment.
A study of esophagectomy specimens with squa-
mous cell carcinoma and adenocarcinoma found
Barrett’s mucosa (without or with dysplasia) in
100% of specimens with an adenocarcinoma and
in 40.6% with squamous cell carcinoma.123 High-
grade squamous dysplasia was present in 10 of the
13 specimens with squamous cell carcinoma, adja-
cent to the squamous tumor. The squamous cell
carcinoma and/or high-grade squamous dysplasia
were separated from the Barrett’s mucosa by nor-
mal squamous epithelium.
Barrett’s adenocarcinoma and squamous cell car-
cinoma share some risk factors in common: age,
male gender, and smoking.124,125 The latter is some-
what controversial in the literature, but there are
reports of a causal relationship between smoking
and Barrett’s adenocarcinoma.126
Squamous carcinoma may be seen in BE as
a component of adenosquamous carcinoma in
which the glandular and squamous components
are intimately admixed. Organ sites that develop
adenocarcinoma can also develop adenosquamous
carcinoma127 and this is thought to represent
tumor transdifferentiation. There are case reports
of adenosquamous carcinoma that support this
contention. Mishima et al. described an adeno-
carcinoma occurring in Barrett’s mucosa where
histological examination showed the focal squa-
mous cell carcinoma component present within
the adenocarcinoma.128 The Barrett’s mucosa sur-
rounding the adenocarcinoma component of the
tumor displayed glandular dysplasia as a precursor
to the adenocarcinoma.
Van Rees et al. found molecular evidence for
the monoclonal origin of both components of
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adenosquamous carcinoma in Barrett’s mucosa.129
The Barrett’s epithelium, the adenocarcinoma, and
the squamous cell carcinoma shared the same allelic
loss on chromosome 9p, and the adenocarcinoma
and the squamous cell carcinoma had the same
allelic loss on chromosomal arms 3p, 5q, 10q,
14q, and 18q. Sequencing of the p53 gene revealed
the same missense mutation in the adenocarcinoma
and the squamous cell carcinoma component.
Squamous islands occur in Barrett’s mucosa,
whether untreated130 or treated after acid
suppression,131,132 where they may be related to
Barrett’s epithelium regression. These squamous
cells situated within the Barrett’s segment could
potentially serve as a source of squamous cell car-
cinoma development. A study analyzing tumor
biomarkers (Ki-67 and p53) suggests that com-
pletely reversed squamous epithelium following
a combination of thermal and proton pump
inhibitor therapy is biologically similar to nor-
mal squamous epithelium and is of low cancer
risk, whereas partially reversed squamous epithe-
lium manifested as squamous islands is accom-
panied by biomarker abnormalities suggesting a
continued cancer risk.133
There are case reports of the occurrence of
squamous cell carcinoma after endoscopic mucosal
ablation134 and radiofrequency ablation (RFA),
used as therapy for Barrett’s mucosa. In the first
report of squamous cell carcinoma after RFA,
Barrett’s mucosa with high-grade dysplasia initially
responded well to RFA with the development of
neosquamous epithelium.135 However, squamous
cell carcinoma rapidly developed. Sanger sequenc-
ing confirmed that the original high-grade dysplasia
and the squamous cell carcinoma had separate
clonal origins. The rapid development after RFA
and occurrence of the squamous tumor at the
same location as the high-grade dysplasia strongly
argue in favor of causal relationship with the
RFA.
To summarize, BE can predispose to, or be asso-
ciated with, squamous cell carcinoma by several
mechanisms (1) shared risk factors that give rise to
squamous and adenocarcinoma as separate tumors,
possibly synchronous; (2) squamous cell carcinoma
occurring as a component in a Barrett’s adenocarci-
noma, likely representing divergent or tumor trans-
differentiation; and (3) as a consequence of medical
or local ablative therapies for Barrett’s mucosa.
Scenarios 2 and 3 can be considered as predisposing
mechanisms.
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